The PCORnet Blood Pressure Home Monitoring Study

Not Applicable

Completed

• Conditions: Hypertension
• Interventions: Device: Standard HBPM; Device: Smartphone-linked HBPM and associated app

• Registration Number: NCT03796689
• Lead Sponsor: University of California, San Francisco

Brief Summary

The PCORnet Blood Pressure Home Monitoring (BP HOME) Study is a patient-level randomized controlled trial that will compare the effectiveness of home blood pressure monitoring (HPBM) with versus without a linked Smartphone application ("app") for helping patients with uncontrolled hypertension achieve a reduction in systolic blood pressure. The trial will be conducted within the National Patient-Centered Clinical Research Network (PCORnet), which supports a research network that enables distributed querying of EHR data in a common data model. It will also use the Eureka Research Platform, an online research platform hosted by UCSF that supports eConsent, online surveys, and data collection from devices such as HBPMs. Data from these two data sources will be used together to accomplish the study aims. Given that HBPM is the guideline-recommended standard of care (without specification of Smartphone linkage), the HPBM devices and the app are all commercially available and currently in use, and that clinicians, with input from patients, will maintain full control of how BP is clinically managed, we believe participation in the project poses minimal risk to participants.

Detailed Description

We have designed a patient-level randomized controlled trial that will compare the effectiveness of Smartphone-linked versus standard HBPM for helping patients with uncontrolled hypertension achieve a reduction in their Systolic Blood Pressure (SBP), and patient satisfaction with the device. Our original plan was to recruit 2000 patients who would be randomized in a 1:1 ratio to receive a Smartphone-linked or standard HBPM. However, to recruit higher diversity with more African Americans and LatinX patients, we extended the recruitment period.\* We will use data from the electronic health record (EHR), an online patient portal, and the home BP monitor (in the Smartphone-linked arm) to collect outcome data for a period of at least 6 months (for the primary outcome), and up to 18 months (for secondary outcomes, depending on enrollment date). The primary BP control outcome will be reduction in SBP, by clinic measurements, at 6 months. The primary patient satisfaction outcome will be the Net Promoter Score derived from self-reported likelihood of recommending the device to a friend, at 6 months.

\*edited after completing recruitment

Study Timeline

• Study First Submitted: 2019-01-04
• Study First Submitted QC: 2019-01-04
• Study First Posted: 2019-01-08
• Study Start: 2019-08-15
• Primary Completion: 2021-10-23
• Study Completion: 2021-10-23
• Results First Submitted: 2022-09-12
• Status Verified: 2022-10
• Results First Submitted QC: 2022-10-24
• Last Update Submitted: 2022-10-24
• Results First Posted: 2022-11-16
• Last Update Posted: 2022-11-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2238

Inclusion Criteria

• Age ≥ 18 years
• At least one ambulatory visit in one of the participating study sites during the past year
• SBP > 145 mmHg at most recent clinic visit (may be treated with BP meds already or not)
• A self-reported commitment to "work on lowering your blood pressure by 10 points or more to reduce your risk of heart attack and stroke"
• Owns a Smartphone (Android or iOS)
• Willing to receive text messages from the study
• Can read/write English well enough to use English-based Smartphone apps and fill out online surveys in English

Read More

Exclusion Criteria

• Has an arm circumference <22 cm or >42 cm
• Owns a functioning HPBM and has used it in the last 3 months

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Standard	Standard HBPM	-
Smartphone-linked	Smartphone-linked HBPM and associated app	-

Primary Outcome Measures

Name	Time	Method
Change in Systolic Blood Pressure (SBP)	Baseline and 6 months	Change is defined by the absolute difference between the SBP measured at the most recent outpatient clinical encounter at the time of enrollment, and the SBP measured at the most recent outpatient clinical encounter 6 months after enrollment. If more than 1 measurement is recorded during a single clinical encounter, the lower/lowest will be used.
Net Promoter Score	6 months	This score is assessed by asking a single question about likelihood of recommending the device to a friend, with options from 1-10 (10 being extremely likely). As per published methods, persons indicating 9 or 10 are considered "Promoters"; persons indicating 7 or 8 are "Passives"; and persons indicating 1-6 are "Detractors". The score is calculated by taking the percent of Promoters and subtracting the percent of Detractors, yielding a score for each group ranging from -100 to 100, with higher scores indicating a better outcome.

Trial Locations

Locations (4)

University of Florida Health; 🇺🇸 Gainesville, Florida, United States

University Medical Center; 🇺🇸 New Orleans, Louisiana, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

University of California, San Francisco; 🇺🇸 San Francisco, California, United States